Regulation, by its nature, is cautious. Agencies tasked with protecting public health are not designed to move fast; they are designed to be rigorous. Yet rare diseases have, from the very beginning, placed regulators in an uncomfortable position. The same caution that protects patients from unsafe or ineffective treatments also, if applied without adaptation, denies […]
Regulation, by its nature, is cautious. Agencies tasked with protecting public health are not designed to move fast; they are designed to be rigorous. Yet
Hi, I’m Susana Londono, a Research Manager at LDA Research, specialising in research across Latin America and Spain. I joined LDA in June 2024, bringing
For most of the twentieth century, the pharmaceutical industry’s relationship with rare diseases could be summarised in a single phrase: studied indifference. The economics were
As medical market research has moved increasingly online, and as social media has widened access to recruitment opportunities, fraud prevention has become more important than
Across the world, an estimated 300 to 400 million people live with a rare disease. Yet for most of the twentieth century, these individuals lived
The Day Something Felt “Not Quite Right” One ordinary day, I suddenly had a nosebleed. That alone isn’t unusual—I’ve had them before. But this time,
